4

ML351

4 Cited Publications

Cat. No.: HY-111310

CAS No.: 847163-28-4

Purity: 99.16%

Target:

Lipoxygenase

Research Areas:

Neurological Disease Metabolic Disease

ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC₅₀ of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

RG100204

1 Cited Publications

Cat. No.: HY-161834

CAS No.: 2140901-88-6

Target:

Pyroptosis Aquaporin NOD-like Receptor (NLR) p38 MAPK

Research Areas:

Infection Metabolic Disease Inflammation/Immunology

RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H ²O ². RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

20-SOLA

1 Cited Publications

Cat. No.: HY-160186

CAS No.: 3084781-89-2

Target:

Cytochrome P450

Research Areas:

Cardiovascular Disease Metabolic Disease Endocrinology

20-SOLA is an orally active 20-HETE antagonist. 20-SOLA greatly ameliorates changes in blood pressure and renal injury associated with a Streptozotocin (STZ) (HY-13753)-diabetic mouse model. 20-SOLA facilitates the restoration of coronary collateral growth (CCG) after ischemic injury. 20-SOLA can be studied for research in cardiovascular diseases and diabetes .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

KOTX1

1 Cited Publications

Cat. No.: HY-164781

CAS No.: 1788963-83-6

Synonyms: MBE1

Target:

Aldehyde Dehydrogenase (ALDH)

Research Areas:

Metabolic Disease

KOTX1 is an orally active and selective ALDH1A3 inhibitor. KOTX1 improves glucose tolerance, insulin secretion and blood sugar levels in diabetic mouse models .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Faricimab

Cat. No.: HY-P99116

CAS No.: 1607793-29-2

Synonyms: RG7716; RO-6867461

Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Glycerol kinase, microorganism

Cat. No.: HY-P2917

CAS No.: 9030-66-4

Synonyms: GyK

Target:

Nuclear Hormone Receptor 4A/NR4A

Research Areas:

Metabolic Disease Inflammation/Immunology

Glycerol kinase, microorganism (GyK) acts as a NR4A1 inhibitor with enzymatic activity. It directly binds to and inhibits the transcription factor NR4A1, thereby negatively regulating hepatic gluconeogenesis and reducing blood glucose levels. Glycerol kinase, microorganism positively regulates UCP1 expression via partial dependence on the β-adrenergic receptor-cAMP-CREB pathway, promotes browning of white adipose tissue and thermogenesis, and further modulates intracellular fatty acid composition and energy metabolism. In diabetic mouse models, overexpression of Glycerol kinase effectively antagonizes NR4A1-induced hyperglycemia, demonstrating potential for improving glucose homeostasis. Glycerol kinase, microorganism can be used for studies on diabetes and obesity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

JBSNF-000028 free base

Cat. No.: HY-151500

CAS No.: 3026599-90-3

Purity: 99.20%

Target:

Amine N-methyltransferase

Research Areas:

Metabolic Disease

JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Isoxazole

Cat. No.: HY-W010649

CAS No.: 288-14-2

Target:

HSP Epigenetic Reader Domain ATP-binding cassette (ABC) transporters Bacterial Fungal Antibiotic

Research Areas:

Infection Metabolic Disease Inflammation/Immunology Cancer

Isoxazole is a member of the five-membered heterocycle drug scaffold. Isoxazole has been used as a BET bromodomain inhibitor and can improve β-cell function in a diabetic mouse model. Isoxazole and its derivatives exhibit broad biological activities (such as antimicrobial, antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, immunomodulatory, analgesic, anti-tuberculosis, and anti-diabetic effects). For example, the bicyclic Isoxazole can act as an HSP90 inhibitor, and the tricyclic Isoxazole is promising as a selective multidrug resistance protein (MRP1) inhibitor .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Leelamine

Cat. No.: HY-W005629

CAS No.: 1446-61-3

Target:

Cannabinoid Receptor PDK-1

Research Areas:

Metabolic Disease Cancer

Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

JBSNF-000028 hydrochloride

Cat. No.: HY-151500B

Purity: 95.64%

Target:

Amine N-methyltransferase

Research Areas:

Metabolic Disease

JBSNF-00002 hydrochloride is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC₅₀ values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 hydrochloride can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC₅₀ being 2.5 μM. JBSNF-00002 hydrochloride exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 hydrochloride can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .

Compare

loading...